not sustainable. cadence should sell themselves to big pharma so ofirmev can placed into an existing sales force that already has multiple drugs.
there's not enough leverage in the current business model.
LMFAO. No answer, you know when you thought about it, no way they need to raise cash, so the only thing you and all the other shorts are left with are hyperbole, deception, confusion and trying to create doubt.
I sleep well tonight knowing I have a stock that will only be accumalted as time goes on, and may be a takeover at any time.
You and the rest of the shorts go to bed tonight realizing you have to cover and it just a matter of how much pain you are willing to put up with knowing the possibility that OFIRMEV would be a great drug in some big pharmas armamterium and could be a take over any day.
SLEEP TIGHT MFer.
at $20M per quarter burn, they have a long way to go before even sniffing profitability. You could be right and the sales ramp is forthcoming and enough to put off a big financing (perhaps relying only on debt), but ofirmev estimates had to be revised lower twice this year already.
you mean sell-estimates are always correct? wow, I guess wall street analysts are geniuses. oh wait, they already lowered 2011 and 2012 estimates twice in the past six months. look out for more downward revisions.
Wang, the revenue estimates for 2012 are 102 million, and those are 'low balled', not what your thinking penis breath. So explain to me how 100 million in revenue for 2012 along with the 94 million they have in cash makes them have to do a capital raise. Let me see the math on this one genius. I can't wait!
the stock isn't trading on beats. it's been stuck in a range for years and will continue to do so. it will break out of the range after you wake up one morning to a press release announcing a 10m share offering.
you're a novice investor if you don't think burn rate matters.